Answers are grounded in this paper and cite their sources.
Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.
No takes yet. Share an insight, caveat, or question.
Switzer et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: